KMT2D and cervical adenocarcinoma: Our cervical adenocarcinoma cohort exhibited genetic diversity, with frequent mutations in PIK3CA (n = 26; 25.5%), TP53 (n = 22; 21.6%), ARID1A (n = 21; 20.6%), KRAS (n = 17; 16.7%), and KMT2D (n = 12; 11.8%) (Figure 2).